Trinity Biotech Announces an Annual Dividend of 15 Cents Per ADR -- an Increase of 50%
April 25 2012 - 07:26AM
Trinity Biotech plc (Nasdaq:TRIB), a leading developer and
manufacturer of diagnostic products for the point-of-care and
clinical laboratory markets, today announced a proposed dividend of
15 cents per ADR.
In 2011, Trinity announced the commencement of an annual
dividend policy and paid a dividend of 10 cents per ADR. This year
the Company is proposing a dividend of 15 cents per ADR,
representing an increase of 50%. The payment of this dividend is
subject to shareholder approval, which will be sought at the
Company's forthcoming AGM to be held on May 25, 2012. Subject to
this approval being granted, the record date will be June 8, 2012
and payment will follow 2 weeks later.
Litigation Reform Act of 1995. Investors are cautioned that such
forward-looking statements involve risks and uncertainties
including, but not limited to, the results of research and
development efforts, the effect of regulation by the United States
Food and Drug Administration and other agencies, the impact of
competitive products, product development commercialisation and
technological difficulties, and other risks detailed in the
Company's periodic reports filed with the Securities and Exchange
Commission.
Trinity Biotech develops, acquires, manufactures and markets
diagnostic systems, including both reagents and instrumentation,
for the point-of-care and clinical laboratory segments of the
diagnostic market. The products are used to detect infectious
diseases and to quantify the level of Haemoglobin A1c and other
chemistry parameters in serum, plasma and whole blood. Trinity
Biotech sells direct in the United States, Germany, France and the
U.K. and through a network of international distributors and
strategic partners in over 75 countries worldwide. For further
information please see the Company's website:
www.trinitybiotech.com.
The Trinity Biotech plc logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=10602
CONTACT: Trinity Biotech plc
Kevin Tansley
(353)-1-2769800
E-mail: kevin.tansley@trinitybiotech.com
Lytham Partners LLC
Joe Diaz, Joe Dorame & Robert Blum
602-889-9700
Trinity Biotech (NASDAQ:TRIB)
Historical Stock Chart
From Feb 2024 to Mar 2024
Trinity Biotech (NASDAQ:TRIB)
Historical Stock Chart
From Mar 2023 to Mar 2024